Former I-Mab chief Joan Shen

Shanghai/Boston biotech NeuShen, led by former I-Mab CEO Joan Shen, banks $80M+ Series B for three clinical-stage brain-health drugs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…

Kyle LaHucik · 2026-09-04

A Shanghai and Boston biotech led by a veteran transpacific drug developer has secured more than $80 million to advance three clinical-stage brain-health drugs. NeuShen Therapeutics disclosed the Series B this ...

Source: Endpoints News